Article, 2024

Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement

International Journal of Dermatology, ISSN 1365-4632, 0011-9059, 10.1111/ijd.17366

Contributors

Chernyshov, Pavel Viktorovich 0000-0001-7275-4651 (Corresponding author) [1] Tomas‐Aragones, Lucia [2] Zuberbier, Torsten 0000-0002-1466-8875 [3] [4] Kocatürk, Emek Özgür 0000-0003-2801-0959 [3] [4] [5] Manolache, Liana 0000-0003-2357-4229 [6] Pustisek, Nives [7] Svensson, Åke [8] Marron, Servando Eugenio 0000-0001-5632-0351 [9] Sampogna, Francesca 0000-0002-7624-3290 [10] Bewley, Anthony Paul 0000-0003-1195-0290 [11] [12] Salavastru, Carmen Maria [13] Koumaki, Dimitra 0000-0001-7074-2374 [14] Augustin, Matthias 0000-0002-4026-8728 [15] Linder, Dennis Michael 0000-0002-0305-3146 [16] Abeni, Damiano D C 0000-0002-0167-7617 [10] Salek, Sam S 0000-0002-4612-5699 [17] Szepietowski, Jacek Cezary 0000-0003-0766-6342 [18] Jemec, Gregor B. [19]

Affiliations

  1. [1] Bogomolets National Medical University
    2. [NORA names: Ukraine; Europe, Non-EU];
  2. [2] University of Zaragoza
    3. [NORA names: Spain; Europe, EU; OECD];
  3. [3] Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany
    4. [NORA names: Germany; Europe, EU; OECD];
  4. [4] Charité - University Medicine Berlin
    5. [NORA names: Germany; Europe, EU; OECD];
  5. [5] Koç University
    6. [NORA names: Turkey; Asia, Middle East; OECD];

Abstract

In this study, the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality of Life and Patient-Oriented Outcomes and Urticaria and Angioedema has examined the Health-Related Quality of Life (HRQoL) measurement in the treatment of urticaria. The Dermatology Life Quality Index was the most frequently used HRQoL instrument in clinical trials on urticaria. Many reports of clinical trials of urticaria gave no exact numeric results related to HRQoL changes, making clear conclusions and comparisons with other studies impossible. The interpretation of HRQoL impairment data is more difficult when assessed by instruments without severity stratification systems. The minimal clinically significant difference (MCID) is a more clinically oriented and relevant parameter than depending on statistically significant changes in HRQoL scores. Therefore, using HRQoL instruments with established MCID data in clinical trials and clinical practice is preferred.

Keywords

Dermatology Life Quality Index, European, European Academy, European Academy of Dermatology and Venereology, HRQoL, HRQoL changes, HRQoL instruments, HRQoL scores, Life Quality Index, Quality Index, Venereology, angioedema, assess treatment effects, changes, clinical practice, clinical trials, clinically significant differences, comparison, conclusions, data, dermatology, differences, effect, health-related quality, health-related quality of life, impairment data, index, instrument, interpretation, life, life measures, measurements, minimal clinically significant difference, outcomes, parameters, patient-oriented, patient-oriented outcomes, position statement, practice, quality, quality of life, quality of life measures, relevant parameters, reports, scores, severity, significant changes, significant difference, statements, statistically, statistically significant changes, stratification system, study, system, treatment, treatment effects, treatment of urticaria, trials, urticaria

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+